The hypothalamic-pituitary-adrenal (HPA) axis is a central neuroendocrine system that regulates the body's stress response, cortisol secretion, and metabolic homeostasis. Chronic HPA axis dysregulation is increasingly recognized as a significant contributor to neurodegenerative disease pathogenesis, particularly in Alzheimer's disease (AD) and Parkinson's disease (PD). This pathway page documents the mechanisms by which HPA axis dysfunction promotes neurodegeneration and explores therapeutic implications.
flowchart TD
A[Chronic Stress] --> B[Hypothalamic PVN Activation]
B --> C[CRH/AVP Release]
C --> D[Anterior Pituitary]
D --> E[ACTH Release]
E --> F[Adrenal Cortex]
F --> G[Cortisol Elevation]
G --> H1[ hippocampal atrophy]
G --> H2[ Tau Hyperphosphorylation]
G --> H3[ Amyloidogenesis]
G --> H4[ Neuroinflammation]
G --> H5[ Synaptic Dysfunction]
H1 --> I[Memory Impairment]
H2 --> I
H3 --> I
H4 --> I
H5 --> I
J[Glucocorticoid Resistance] --> K[Negative Feedback Failure]
K --> B
L[APOE4 Carrier] -.->|Increased Vulnerability| G
M[Chronic Inflammation] -.->|Amplify| G
The HPA axis represents the body's primary system for responding to physiological and psychological stress. Under normal conditions, acute stress activates the HPA axis, leading to cortisol release that mobilizes energy resources and prepares the body for "fight or flight" responses. However, chronic stress and sustained cortisol elevation have deleterious effects on brain structure and function.
In neurodegenerative diseases, HPA axis dysfunction manifests as:
- Elevated basal cortisol levels - consistently elevated cortisol in AD and PD patients
- Diurnal rhythm disruption - flattened cortisol curves, particularly in AD
- Negative feedback impairment - glucocorticoid receptor resistance
- dexamethasone non-suppression - failure to suppress cortisol in DST
Cortisol exerts its effects primarily through two glucocorticoid receptor (GR) isoforms:
- GRα - cytoplasmic receptor that translocates to nucleus upon ligand binding, regulating gene transcription
- GRβ - dominant-negative isoform that can inhibit GRα function
In neurodegenerative diseases, GR signaling is impaired through:
- Receptor downregulation - reduced GR expression in hippocampus and prefrontal cortex
- Post-translational modifications - altered phosphorylation, sumoylation
- Cofactor dysregulation - altered recruitment of transcriptional coactivators
- GRβ overexpression - increased dominant-negative isoform in AD brain
Elevated cortisol promotes tau pathology through multiple mechanisms:
- GSK3β activation - cortisol enhances glycogen synthase kinase-3β activity, a key tau kinase
- PP2A inhibition - cortisol suppresses protein phosphatase 2A, reducing tau dephosphorylation
- cAMP elevation - cortisol increases cAMP levels, activating PKA which phosphorylates tau
- BBB permeability - cortisol increases blood-brain barrier permeability to peripheral proteins
¶ Cortisol and Amyloidogenesis
Cortisol influences amyloid-β metabolism through:
- APP expression - glucocorticoids upregulate amyloid precursor protein gene expression
- BACE1 activity - cortisol increases β-secretase activity
- Aβ clearance - cortisol impairs amyloid clearance via reduced LRP1 expression
- Aβ aggregation - cortisol promotes Aβ oligomerization
The hippocampus is particularly vulnerable to cortisol-induced damage:
- Neuronal loss - cortisol promotes hippocampal neuronal apoptosis
- Dendritic atrophy - chronic cortisol reduces dendritic complexity
- Neurogenesis impairment - cortisol inhibits adult hippocampal neurogenesis
- Synaptic dysfunction - cortisol reduces spine density and LTP
Cortisol affects prefrontal cortex function:
- Executive dysfunction - working memory and cognitive flexibility impairments
- Dendritic retraction - reduced dendritic branching in Layer II/III neurons
- Glutamate toxicity - enhanced NMDA receptor activity
The amygdala shows opposite effects:
- Enhanced fear conditioning - cortisol potentiates fear memory consolidation
- Neuronal hypertrophy - chronic stress can increase amygdala volume
- Anxiety disorders - HPA axis dysregulation in anxiety comorbidity
HPA axis abnormalities in AD include elevated basal cortisol levels (20-30% higher than controls) [1], exaggerated cortisol response to stress [2], reduced glucocorticoid receptor binding in the hippocampus [3], and dexamethasone non-suppression in approximately 50% of patients [4]. These abnormalities correlate with disease severity and progression.
APOE4 carriers show particularly pronounced HPA axis dysregulation:
- Higher cortisol responses to stress
- Reduced glucocorticoid receptor density
- Enhanced vulnerability to cortisol-induced neurotoxicity
HPA axis dysfunction in PD:
- Elevated cortisol - correlated with disease severity
- Autonomic dysfunction - impaired cortisol circadian rhythm
- Stress intolerance - exaggerated cortisol response to minor stressors
- Dopamine-GR interaction - dopamine can modulate GR signaling
¶ ALS and FTD
HPA axis abnormalities in motor neuron diseases:
- Elevated basal cortisol levels
- Impaired stress response
- Correlation with disease progression
HPA axis dysfunction and neuroinflammation form a vicious cycle:
- Cytokine effects - IL-1β, IL-6, TNF-α activate HPA axis
- Glucocorticoid resistance - chronic inflammation leads to GR desensitization
- Feedback failure - impaired negative feedback increases inflammation
- Microglial activation - cortisol modulates microglial phenotype
| Drug Class |
Mechanism |
Status |
| Metyrapone |
11β-hydroxylase inhibitor |
Phase II for AD |
| Mifepristone |
GR antagonist |
Investigational |
| Ketoconazole |
Steroidogenesis inhibitor |
Off-label use |
| SSRIs |
5-HT modulation of HPA |
Approved for depression |
- Stress reduction - mindfulness, meditation, yoga
- Sleep optimization - normalize circadian cortisol rhythm
- Exercise - moderate exercise reduces cortisol
- Dietary interventions - anti-inflammatory diets
- GR modulators - selective glucocorticoid receptor modulators (SGRMs)
- CRH receptor antagonists - block upstream HPA activation
- Neurosteroid modulators - allopregnanolone-based therapies
- Gene therapy - viral delivery of GR isoforms
HPA axis-related biomarkers for neurodegeneration:
- Basal cortisol - serum/CSF cortisol levels
- Cortisol/DHEA ratio - more predictive than cortisol alone
- Dexamethasone suppression test - measure feedback sensitivity
- GR expression - peripheral blood mononuclear cell GR mRNA
- Salivary cortisol - diurnal curve assessment
Current research priorities:
- Mechanistic studies - delineate cortisol vs. cortisone effects
- Biomarker development - HPA axis metrics for disease progression
- Clinical trials - GR antagonists in AD and PD
- Precision medicine - APOE-stratified interventions
- Combination therapies - HPA modulation + disease-modifying treatments
The study of Hpa Axis Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Sapolsky RM. Stress and the brain: individual variability and the inverted-U. Nat Neurosci. 2015;18(10):1344-1346.
-
Ouanes S, Popp J. High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature. Front Aging Neurosci. 2019;11:43.
-
Brett CA, Satlin A. Glucocorticoids and Alzheimer's disease. Pharmacol Ther. 2023;241:108314.
-
Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci. 2009;10(6):434-445.
-
Pedersen WA, Wan R, Mattson MP. Impact of glucocorticoid sensitivity on the onset and progression of neurodegenerative disorders. Ann N Y Acad Sci. 2000;917:638-646.
-
Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006;26(35):9047-9056.
-
Csernansky JG, Dong H, Fagan AM, et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry. 2006;163(12):2164-2169.
-
Pistollato F, Canudo MI. The Role of the Hypothalamic-Pituitary-Adrenal (HPA) Axis in Neurodegenerative Diseases: Current State of the Art. Int J Mol Sci. 2021;22(11):5734.
-
De Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci. 2005;6(6):463-475.
-
Vyas S, Rodrigues AJ, Silva JM, et al. Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration. Neural Plast. 2016;2016:6391686.